RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study
Open Access
- 21 November 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 115 (2) , 222-223
Abstract
Cold and colleagues ( 1) report findings by menopausal hormone therapy (MHT) use without providing the hormone therapy category. Both estrogen plus progestin and estrogen alone are described as increasing breast cancer incidence and mortality in women without breast cancer history, citing 2 large observational studies published in 2019. However, not cited was a 2020 report from 2 Women’s Health Initiative randomized placebo-controlled trials with 27 347 postmenopausal women with no prior breast cancer and mammogram clearance, evaluating estrogen plus progestin and estrogen alone (for women with prior hysterectomy). After 20 years of follow-up and 1565 incident breast cancers, estrogen plus progestin increased breast cancer incidence, whereas estrogen alone decreased breast cancer incidence and breast cancer mortality ( 2). Against such randomized trial findings, it is inappropriate to report findings without describing the MHT therapy category because differential effects on breast cancer outcomes could be anticipated. The authors should provide this information.Keywords
Funding Information
- National Cancer Institute (R01 CA119171, R01 CA10921)
- Women’s Health Initiative
- National Heart, Lung, and Blood Institute
- National Institutes of Health
- U.S. Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, R25CA203650)
This publication has 7 references indexed in Scilit:
- Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort StudyJNCI: Journal of the National Cancer Institute, 2022
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical TrialsJAMA, 2020
- Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trialEuropean Journal of Cancer, 2013
- Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer SurvivorsJNCI: Journal of the National Cancer Institute, 2008
- Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidenceBreast Cancer Research, 2005
- Invited Commentary: Circular EpidemiologyAmerican Journal of Epidemiology, 1999
- Practical Statistics for Medical Research1990